This is a multicenter randomized double-blind placebo controlled parallel group study evaluating the efficacy and safety of GC150526 or placebo in patients with a clinical diagnosis of acute stroke. This drug is a potent glycine antagonist. Glycine is a co-agonist of the NMDA receptor for glutamine-induced and neuroexcitation. Since this NMDA receptor by stimulation of this NMDA receptor by glutamate may be cytotoxic during cerebral ischemia, antagonism of this receptor may be beneficial.
Showing the most recent 10 out of 753 publications